Pharmacogenetics of new classes of antidiabetic drugs

Authors

  • Selma Imamovic Kadric Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0003-2926-431X
  • Aida Kulo Cesic Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0002-5891-3780
  • Tanja Dujic Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0001-9221-1208

DOI:

https://doi.org/10.17305/bjbms.2021.5646

Keywords:

Type 2 diabetes, pharmacogenetics, personalized medicine, new antidiabetics

Abstract

Type 2 diabetes (T2D) has a continuously rising prevalence worldwide. Pharmacogenetics has been recognized as a promising concept for pharmacological treatment of T2D, as antidiabetic drugs are not equally effective and safe for all patients, and the costs of diabetes treatment are increasing. The latest published guidelines on T2D treatment firmly endorse the use of newer antidiabetic drugs, sodium-glucose cotransporter-2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-IVi), and glucagon-like peptide-1 receptor agonists (GLP-1RA), considering their satisfactory pharmacological effect and good safety profile. Furthermore, SGLT2i and GLP-1RA show protective effects in patients with established atherosclerotic cardiovascular disease and chronic kidney disease. However, there has been growing evidence that the effectiveness and safety of these drug classes could depend on genetic variability. Here, we summarized the results of the published studies on the pharmacogenetic biomarkers for the three drug classes. A number of genetic variations have been investigated so far. The explored candidate genes mostly encode drug targets, drug-metabolizing enzymes, and genes linked to T2D risk. Although many of the results are promising, it is still necessary to obtain more information from larger controlled studies to confirm their clinical significance. This approach may lead towards more personalized treatment for patients with T2D.

Author Biographies

  • Aida Kulo Cesic, Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

    Associate Professor

    Department of Pharmacology, Clinical Pharmacology and Toxicology

  • Tanja Dujic, Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

    Associate Professor

    Department of Biochemistry & Clinical Analysis

Pharmacogenetics of new classes of antidiabetic drugs

Downloads

Additional Files

Published

01-12-2021

Issue

Section

Reviews

Categories

How to Cite

1.
Pharmacogenetics of new classes of antidiabetic drugs. Biomol Biomed [Internet]. 2021 Dec. 1 [cited 2024 Feb. 23];21(6):659-71. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/5646